Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Sword who wrote (784)	3/16/2000 10:08:00 PM
From: byhiselo	Read Replies (1) \| Respond to of 1298

sword, joined you but took the options route today apr 40, 45, and 50 calls as well as stock... mucho $$ or mea culpa and yes it feels like gambling ;) cheers

To: Sword who wrote (784)	3/24/2000 7:51:00 AM
From: ayn rand	Read Replies (1) \| Respond to of 1298

FOSTER CITY, Calif., March 24, 2000-Cell Genesys (Nasdaq: CEGE) CELL GENESYS REPORTS SUCCESSFUL PRECLINICAL STUDIES OF LENTIVIRAL GENE THERAPY FOR HEMOPHILIA A CEGE today announced that Inder Verma, Ph.D., and colleagues at The Salk Institute have reported the successful use of lentiviral vectors in preclinical studies of hemophilia A, an inherited bleeding disorder. In addition, Flavia Borellini, Ph.D. and colleagues at Cell Genesys reported the successful development of the scaleable manufacturing technology for lentiviral vectors required for clinical studies in hemophilia and other serious diseases. These presentations were made in Washington D.C. at the Third Workshop on Gene Therapies for Hemophilia sponsored by the National Hemophilia Foundation. cellgenesys.com